{"id":"NCT00422292","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","officialTitle":"An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2009-01","completion":"2009-04","firstPosted":"2007-01-15","resultsPosted":"2011-06-02","lastUpdate":"2016-04-14"},"enrollment":1664,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Meningitis","Measles","Mumps","Rubella","Varicella"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide Diphtheria Conjugate Vaccine","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide Diphtheria Conjugate Vaccine","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide Diphtheria Conjugate Vaccine","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Measles, Mumps, Rubella and Varicella","otherNames":["ProQuad®","M-M-R®II"]}],"arms":[{"label":"Menactra® at 9 and 12 Months","type":"EXPERIMENTAL"},{"label":"Menactra® at 9 Months and Menactra® + MMRV at 12 Months","type":"EXPERIMENTAL"},{"label":"Menactra® at 9 Months and Menactra® + PCV at 12 Months","type":"EXPERIMENTAL"},{"label":"MMRV + PCV at 12 Months","type":"ACTIVE_COMPARATOR"}],"summary":"This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers.\n\nPrimary Objectives:\n\n* To evaluate the antibody responses induced by Measles, Mumps, Rubella, and Varicella (MMRV) vaccine when administered alone or concomitantly with Menactra vaccine.\n* To evaluate the antibody responses induced by Pneumococcal Conjugated Vaccine (PCV) when administered alone or concomitantly with Menactra vaccine.\n\nObservational Objectives:\n\nSafety - To describe the safety profile throughout the course of the study from Day 0 up to 6 months after the last study vaccination\\[s\\]) in subjects in the study groups.\n\nImmunogenicity:\n\n\\- To describe the antibody responses to meningococcal serogroups A, C, Y, and W-135, 30 days after the first and second Menactra vaccine administration in a subset of subjects in the first study group.","primaryOutcome":{"measure":"Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only)","timeFrame":"Day 30 after the 12-month vaccination","effectByArm":[{"arm":"Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months","deltaMin":98,"sd":null},{"arm":"Group 4: MMRV + PCV at 12 Months","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":88,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":257},"commonTop":["Otitis media","Upper respiratory tract infection","Diarrhoea","Pyrexia","Teething"]}}